Vaccines
Science in Vaccines
Beyfortus® Real-World Effectiveness: Meta-Analysis
Systematic review shows Beyfortus® reduces RSV hospitalizations by 83% and ICU admissions by 81% in real-world infant immunization programs.
Expert consensus on the burden of RSV disease and the utility of nirsevimab for disease prevention and
protection of infants
Please log in or register to continue reading.
Login For Healthcare Professionals
HCP Verification Required
We are in the midst of verifying your registration. You will receive an email confirmation to access Campus Sanofi once your verification is complete.
RESEND SUCCESS
Please check you email for verification emali.
Restricted Content
You do not have the correct verified role to view this content.
You are almost set!
Success
Thank you for registering. Please validate your email by clicking on the link in the email sent to you. Once your registration has been validated, you will receive a confirmation email to log in to Campus Sanofi.
Patient-Video
Request-form